Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chen, Zhenghu ^a,b   Wang, Zhenyu ^c,d   Pang, Jonathan C ^b   Yu, Yang ^b   Bieerkehazhi, Shayahati ^c,e   Lu, Jiaxiong ^a,b   Hu, Ting ^b,f   Zhao, Yanling ^b   Xu, Xin ^b   Zhang, Hong ^c   Yi, Joanna S ^b   Liu, Shangfeng ^a,g   Yang, Jianhua ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^e XINJIANG MEDICAL UNIVERSITY   (China)

^f CENTRAL SOUTH UNIVERSITY   (China)

^g FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CDK2 PROTEIN, HUMAN; CDK9 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; DINACICLIB; DOXORUBICIN; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE INHIBITOR; PYRIDINIUM DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; MOUSE; NEUROBLASTOMA; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 9; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; NEUROBLASTOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINIUM COMPOUNDS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84977272887     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29090     Document Type: Article

References (56)

1. Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3, 203-216 (2003).
2. Seeger, R. C. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol. 21, 229-237 (2011).
3. Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 45, 279-284 (2013).
4. Sherr, C. J. Cancer cell cycles. Science 274, 1672-1677 (1996).
5. Nurse, P., Masui, Y. & Hartwell, L. Understanding the cell cycle. Nat Med. 4, 1103-1106 (1998).
6. Lim, S. & Kaldis, P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140, 3079-3093 (2013).
7. Drapkin, R., Le Roy, G., Cho, H., Akoulitchev, S. & Reinberg, D. Human cyclin-dependent kinase-activating kinase exists in three distinct complexes. Proc Natl Acad Sci USA. 93, 6488-6493 (1996).
8. Bregman, D. B., Pestell, R. G. & Kidd, V. J. Cell cycle regulation and RNA polymerase II. Front Biosci. 5, D244-257 (2000).
9. Nemet, J., Jelicic, B., Rubelj, I. & Sopta, M. The two faces of Cdk8, a positive/negative regulator of transcription. Biochimie 97, 22-27 (2014).
10. Chung, J. et al. Expression of RB C pocket fragments in HSF induces delayed cell cycle progression and sensitizes to apoptosis upon cellular stresses. Cell Prolif. 35, 247-256 (2002).
11. Goodrich, D. W., Wang, N. P., Qian, Y. W., Lee, E. Y. & Lee, W. H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67, 293-302 (1991).
12. Wu, C. L., Zukerberg, L. R., Ngwu, C., Harlow, E. & Lees, J. A. In vivo association of E2F and DP family proteins. Mol Cell Biol. 15, 2536-2546 (1995).
13. Munger, K. & Howley, P. M. Human papillomavirus immortalization and transformation functions. Virus Res. 89, 213-228 (2002).
14. Hinds, P. W. et al. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70, 993-1006 (1992).
15. Brugarolas, J. et al. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci USA. 96, 1002-1007 (1999).
16. Akiyama, T., Ohuchi, T., Sumida, S., Matsumoto, K. & Toyoshima, K. Phosphorylation of the retinoblastoma protein by cdk2. Proc Natl Acad Sci USA. 89, 7900-7904 (1992).
17. Zhu, X., Ohtsubo, M., Bohmer, R. M., Roberts, J. M. & Assoian, R. K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol. 133, 391-403 (1996).
18. Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 13, 261-291 (1997).
19. Malumbres, M. & Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1, 222-231 (2001).
20. Criscitiello, C., Viale, G., Esposito, A. & Curigliano, G. Dinaciclib for the treatment of breast cancer. Expert Opin Investig Drugs 23, 1305-1312 (2014).
21. Flynn, J. et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia 29, 1524-9 (2015).
22. Gregory, G. P. et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia 29, 1437-1441 (2015).
23. Abdullah, C., Wang, X. & Becker, D. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma: functional analysis and molecular targeting of cyclin-dependent kinase family members in advanced melanoma. Cell Cycle 10, 977-988 (2011).
24. Hu, C. et al. Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. Mol Cancer Ther. 14, 1532-1539 (2015).
25. Stephenson, J. J. et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung cancer 83, 219-223 (2014).
26. Chipumuro, E. et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159, 1126-1139 (2014).
27. Rader, J. et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 19, 6173-6182 (2013).
28. Dolman, M. E. et al. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clin Cancer Res. 21, 5100-5109 (2015).
29. Ren, J. et al. Lupiwighteone induces cell cycle arrest and apoptosis and activates the Nrf2/ARE pathway in human neuroblastoma cells. Biomed Pharmacother 69, 153-161 (2015).
30. Loschmann, N. et al. Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. Transl Oncol 6, 685-696 (2013).
31. Delehouze, C. et al. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene 33, 5675-5687 (2014).
32. Bettayeb, K. et al. CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. Genes & cancer 1, 369-380 (2010).
33. Parry, D. et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 9, 2344-2353 (2010).
34. Carlson, B. A., Dubay, M. M., Sausville, E. A., Brizuela, L. & Worland, P. J. Flavopiridol induces G1 arrest with inhibition of cyclindependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56, 2973-2978 (1996).
35. Manohar, S. M., Rathos, M. J., Sonawane, V., Rao, S. V. & Joshi, K. S. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res. 35, 821-830 (2011).
36. Kohl, N. E. et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 35, 359-367 (1983).
37. Weiss, W. A., Aldape, K., Mohapatra, G., Feuerstein, B. G. & Bishop, J. M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985-2995 (1997).
38. Rasmuson, A. et al. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLOS One 7, e51297 (2012).
39. Quarta, C. et al. Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice. Mol Imaging Biol. 15, 194-202 (2013).
40. Hall, M. & Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 68, 67-108 (1996).
41. Molenaar, J. J. et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci USA 106, 12968-12973 (2009).
42. Canduri, F., Perez, P. C., Caceres, R. A. & de Azevedo, W. F., Jr. CDK9 a potential target for drug development. Med Chem. 4, 210-218 (2008).
43. Chao, S. H. & Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem. 276, 31793-31799 (2001).
44. Senderowicz, A. M. & Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 92, 376-387 (2000).
45. Byrd, J. C. et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92, 3804-3816 (1998).
46. Hussain, S. R. et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 111, 3190-3199 (2008).
47. Mahoney, E. et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 120, 1262-1273 (2012).
48. Blachly, J. S. & Byrd, J. C. Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma 54, 2133-2143 (2013).
49. Paruch, K. et al. Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. ACS Med Chem Lett. 1, 204-208 (2010).
50. Johnson, A. J. et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 26, 2554-2557 (2012).
51. Kumar, S. K. et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 125, 443-448 (2015).
52. Nguyen, T. K. & Grant, S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1-and 5-dependent mechanism. Mol Cancer Ther. 13, 662-674 (2014).
53. Cheng, J. et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 5, e1079 (2014).
54. Zhang, H. et al. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis 20, 50-62 (2015).
55. Fan, Y. et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase. J Exp Med 211, 313-328 (2014).
56. Patterson, D. M., Shohet, J. M. & Kim, E. S. Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol Chapter 14, Unit 14-17 (2011).